NVG-291: Nerve Regeneration — Evidence vs. Hype
A viral X post claims a paralyzed patient walked after taking NVG-291. Here is what the peer-reviewed science actually shows: a real PTPσ-modulating peptide with strong rat data and, so far, zero published human efficacy results.
How It Works
After injury, chondroitin sulfate proteoglycans (CSPGs) in the glial scar bind the receptor PTPσ and lock growth cones in a non-growing "dystrophic" state. ISP is a membrane-permeable mimetic of the PTPσ wedge domain that binds PTPσ and relieves CSPG-mediated inhibition (Lang et al., Nature 2015).
Releasing that brake let severed fibers sprout: in rat contusion SCI, systemic peptide over weeks restored serotonergic innervation below the lesion and improved both locomotor and urinary function (Lang et al., Nature 2015).
ISP modulation of PTPσ increased Cathepsin B secretion, degrading the inhibitory CSPG matrix to enhance axon outgrowth — one mechanism behind the regrowth (Tran et al., J Neurosci 2018).
Modulating the proteoglycan receptor regulated RhoA/CRMP2 pathways and promoted axonal myelination in follow-up work (Neurosci Lett 2021) — but this is all animal/cell data.
What the Data Shows
Key Takeaways
- NVG-291 is NervGen Pharma’s clinical candidate based on ISP (intracellular sigma peptide), a membrane-permeable mimetic of the PTPσ wedge domain (Lang et al., Nature 2015).
- Its mechanism is releasing the brake that scar CSPGs place on axon regrowth by modulating the receptor PTPσ — demonstrated in vitro and in rodents (PMID 25470046; PMID 29760175).
- In rat spinal-cord-injury models, the systemic peptide restored serotonergic innervation below the lesion and improved locomotor and urinary function (PMID 25470046).
- Benefits extended to peripheral nerve injury — more regenerated axons, reduced muscle atrophy, better motor-unit responses in rats (PMID 33433490) — and to sensory recovery after dorsal-root injury (PMID 30393073).
- The compound advanced into human testing: a Phase 1 safety study and a Phase 1b/2 in chronic spinal cord injury (NervGen) — early-stage, safety/exploratory in nature.
- There are NO published peer-reviewed human efficacy results — every recovery finding above is preclinical (rats), and animal results do not reliably predict human outcomes.
- The viral "paralyzed patient walked with a walker" anecdote is unverified and is not evidence: no trial has reported that outcome in any peer-reviewed source.
- Effects are not universal even in animals — disrupting PTPσ did not prevent sympathetic axon dieback after myocardial infarction (PMID 26616238).
- Optimal human dose, treatment window, durability of any benefit, and long-term safety are all unknown.
- NVG-291 is an investigational drug, not a research chemical or supplement — it is not sold by peptide vendors, and material sold online as "NVG-291" carries identity and purity risk.
Frequently Asked Questions
What is NVG-291?
NVG-291 is an investigational nerve-regeneration drug from NervGen Pharma. It is a clinical form of ISP (intracellular sigma peptide), a small peptide that modulates the receptor PTPσ to release the "brake" that scar tissue (CSPGs) places on regrowing nerve fibers. The underlying science was published by Jerry Silver’s Case Western lab in Nature in 2015 (PMID 25470046).
Does NVG-291 make paralyzed people walk?
There is no peer-reviewed human efficacy data showing that. The viral claim of a paralyzed patient walking is an unverified anecdote, not a trial result. Locomotor recovery has been demonstrated in spinal-cord-injured rats (PMID 25470046), and NVG-291’s human Phase 1b/2 spinal-cord-injury trial is ongoing without any published efficacy readout. Treat the walking story as hype until a trial reports it.
How does NVG-291 work?
After nerve injury, chondroitin sulfate proteoglycans in the glial scar bind the receptor PTPσ and stall regenerating axons. NVG-291/ISP is a membrane-permeable mimetic of the PTPσ wedge domain that relieves this CSPG-mediated inhibition, allowing axons to sprout and, in animals, restoring some function (PMID 25470046; PMID 29760175).
Is NVG-291 approved or available to buy?
No. NVG-291 is an investigational drug in early-phase human trials — it is not FDA-approved, not a dietary supplement, and not sold by peptide research-chemical vendors. Anything marketed online as "NVG-291" is unverified and carries identity and purity risk.
What evidence actually supports NVG-291?
The strong evidence is preclinical: rat spinal-cord-injury recovery (PMID 25470046), peripheral-nerve-injury motor recovery (PMID 33433490), dorsal-root sensory recovery (PMID 30393073), and automated-gait improvement (PMID 30627839), plus mechanism work on CSPG clearance and myelination (PMID 29760175; PMID 34166723). Human efficacy data has not yet been published.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
NVG-291 is an investigational drug in early-phase human trials; it is not FDA-approved and not a dietary supplement.
No peer-reviewed human efficacy results exist to date. Preclinical (animal) findings do not reliably predict human outcomes.